Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Necrosis

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    422 result(s) found for: Necrosis. Displaying page 6 of 22.
    «« First « Previous 2  3  4  5  6  7  8  9  10  Next» Last»»
    EudraCT Number: 2019-000889-38 Sponsor Protocol Number: 2019/MyJIA Start Date*: 2020-09-16
    Sponsor Name:Oslo University Hospital
    Full Title: Strategies towards personalised treatment in Juvenile Idiopathic Arthritis (JIA): An open randomised multicentre blinded-assessor trial assessing the effectiveness of intra-articular glucocortico...
    Medical condition: Juvenile idiopathic arthritis is characterised by inflamed joints and is the most common chronic rheumatic disease in childhood and adolescence that potentially lead to disability due to joint dama...
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-005860-69 Sponsor Protocol Number: ODEN Start Date*: 2021-05-10
    Sponsor Name:University of Gothenburg
    Full Title: OSU6162 as add-on in SSRI/SNRI-resistant depression (ODEN): a double-blind, placebo-controlled evaluation of efficacy and safety.
    Medical condition: Depression
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-004315-31 Sponsor Protocol Number: CaEP-B Start Date*: 2020-04-20
    Sponsor Name:Julie Gehl
    Full Title: PHASE II INVESTIGATION OF THE HISTOPATHOLOGIC EFFECT OF CALCIUM ELECTROPORATION ON CANCER IN THE SKIN
    Medical condition: Cutaneous metastases from solid cancer of any histology
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10026693 Malignant skin neoplasm NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-002579-37 Sponsor Protocol Number: Metformina-Bone Start Date*: 2020-11-18
    Sponsor Name:ISTITUTO ORTOPEDICO RIZZOLI
    Full Title: Metformin as maintenance therapy in bone sarcomas at high risk of relapse
    Medical condition: Osteosarcoma and Ewing's Sarcoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10023676 Lactic acidosis PT
    20.1 10027433 - Metabolism and nutrition disorders 10000491 Acidosis lactic LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-000482-32 Sponsor Protocol Number: CNTO1959PSA3005 Start Date*: 2021-08-02
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 3B, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants with Active Psoriatic Arthri...
    Medical condition: Psoriatic Arthritis
    Disease: Version SOC Term Classification Code Term Level
    21.0 10028395 - Musculoskeletal and connective tissue disorders 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Trial now transitioned) HU (Trial now transitioned) BG (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-004076-13 Sponsor Protocol Number: 5 Start Date*: 2006-11-28
    Sponsor Name:Huvud- hals- lung- och hudcancer, Tema Cancer Karolinska Universitetssjukhuset
    Full Title: Secar I Part I: A study of MTD of Sodium selenite in patients with advanced carcinoma. A phase I study. Amendment 5: continuous treatment
    Medical condition: Patients with stage III or IV cancer in whom first and second line treatment have been given but who have tumours that are still progressing, giving symptomes. The patients must be in a fairly good...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2022-003877-48 Sponsor Protocol Number: TAK-662-1501 Start Date*: 2022-12-21
    Sponsor Name:Takeda
    Full Title: An Open-Label, Single-Dose, Phase 1/2 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Human Protein C (TAK-662) for the Treatment of Congenital Protein C Deficiency in Japanese ...
    Medical condition: Congenital Protein C Deficiency
    Disease: Version SOC Term Classification Code Term Level
    20.1 10010331 - Congenital, familial and genetic disorders 10051298 Protein C deficiency PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2015-005308-27 Sponsor Protocol Number: CL04041025 Start Date*: 2016-06-07
    Sponsor Name:R-Pharm International LLC
    Full Title: A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects with Moderately to Severely Active Rheumatoid Arthri...
    Medical condition: Moderately to Severely Active Rheumatoid Arthritis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed) HU (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-016970-33 Sponsor Protocol Number: MACI00809 Start Date*: 2011-03-17
    Sponsor Name:Genzyme Europe BV
    Full Title: An Extension Protocol for Participants of Genzyme-Sponsored Prospective, Randomized, Open-Label, Parallel-Group, Multicenter Study of Matrix-Induced Autologous Chondrocyte Implantation (MACI® impl...
    Medical condition: Symptomatic Articular Cartilage Defects of the Femoral Condyle including the Trochlea. Osteochondritis dissecans lesions that do not require a bone graft.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10028395 - Musculoskeletal and connective tissue disorders 10031231 Osteochondritis dissecans LLT
    14.1 10022117 - Injury, poisoning and procedural complications 10007705 Cartilage damage LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed) CZ (Completed) GB (Completed) SE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2017-002804-29 Sponsor Protocol Number: PA0011 Start Date*: 2019-06-26
    Sponsor Name:UCB Biopharma SRL
    Full Title: A MULTICENTER, PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF BIMEKIZUMAB IN THE TREATMENT OF SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS
    Medical condition: Psoriatic Arthritis
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) CZ (Completed) IT (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2005-005362-36 Sponsor Protocol Number: SiLVER 05 Start Date*: 2006-06-27
    Sponsor Name:Regensburg University Hospital
    Full Title: A PROSPECTIVE RANDOMISED, OPEN-LABELED, TRIAL COMPARING SIROLIMUS-CONTAINING VERSUS mTOR-INHIBITOR-FREE IMMUNOSUPRESSION IN PATIENTS UNDERGOING LIVER TRANSPLANTATION FOR HEPATOCELLULAR CARCINOMA
    Medical condition: Prophylaxis against liver transplant rejection in patients undergoing liver transplantation for hepatocellular carcinoma (HCC)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10050434 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) GB (Completed) SE (Completed) BE (Completed) NO (Completed) AT (Completed) ES (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-000609-38 Sponsor Protocol Number: D5170C00002 Start Date*: 2016-05-10
    Sponsor Name:Allergan Limited
    Full Title: A Phase 2B Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MEDI2070 in Subjects with Moderate to Severe Crohn’s Disease Who Have Failed or Are Intolerant t...
    Medical condition: Crohn's Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) CZ (Prematurely Ended) NL (Prematurely Ended) ES (Prematurely Ended) BG (Completed) HU (Completed) BE (Completed) IT (Prematurely Ended) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-022378-15 Sponsor Protocol Number: VT-4001-001-SP Start Date*: 2011-05-25
    Sponsor Name:Nycomed GmbH
    Full Title: VELVET (Veltuzumab various doses exploratory trial), a randomized, double blind, placebo controlled, multicentre, multinational phase II dose range finding trial in subjects with moderate to severe...
    Medical condition: Rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    14.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) GB (Prematurely Ended) ES (Prematurely Ended) CZ (Prematurely Ended) HU (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-000530-37 Sponsor Protocol Number: 24978 Start Date*: 2004-09-16
    Sponsor Name:Serono International S.A.
    Full Title: A multicentre, randomised, double blind, placebo controlled phase III study of subcutaneously administered onercept in the initial treatment and continued treatment after extended therapy in subjec...
    Medical condition: Psoriasis is an inflammatory skin disorder that affects between 1 and 2% of the population. It is characterised by an increased proliferation of the epidermis, and presents as well-defined thickene...
    Disease: Version SOC Term Classification Code Term Level
    7.0 10037153 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) LV (Completed) EE (Completed)
    Trial results: View results
    EudraCT Number: 2004-003778-27 Sponsor Protocol Number: 0881A8-205 Start Date*: 2005-03-30
    Sponsor Name:Wyeth Research Division of Wyeth Pharmaceuticals Inc. Clinical resaearch and Development
    Full Title: A Randomized Double-Blind Placebo Controlled Trial Evaluating the Safety and Efficacy of Etanercept 25 mg Twice Weekly in Subjects with Moderate to Severe Persistent Asthma
    Medical condition: Moderate to severe asthmatics
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) FI (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2023-000169-14 Sponsor Protocol Number: INES Start Date*: 2023-05-03
    Sponsor Name:Fondazione Santobono Pausilipon ONLUS
    Full Title: Phase II Prospective Multicenter Study of High-Dose Treosulfan/Melphalan as Consolidation Treatment in Newly Diagnosed High-Risk and Very High-Risk Ewing Sarcoma
    Medical condition: Ewing Sarcoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015560 Ewing's sarcoma PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-000939-33 Sponsor Protocol Number: MLN0002-3026 Start Date*: 2015-11-11
    Sponsor Name:Takeda Development Centre Europe, Ltd.
    Full Title: A Randomized, Double-Blind, Double-Dummy, Multicenter, Active-Controlled Study to Evaluate the Efficacy and Safety of Vedolizumab IV Compared to Adalimumab SC in Subjects With Ulcerative Colitis
    Medical condition: Ulcerative Colitis
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004856 10045365 Ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) SK (Completed) NL (Completed) BG (Completed) GB (Completed) DE (Completed) HU (Completed) BE (Completed) ES (Completed) LV (Completed) EE (Completed) LT (Completed) PL (Completed) DK (Completed) PT (Completed) HR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-004319-37 Sponsor Protocol Number: 001.4 Start Date*: 2019-06-19
    Sponsor Name:Medical University of Vienna, Department of Surgery
    Full Title: A prospective, randomised, single-blind explorative study to investigate the efficacy and safety of fat graft enrichment with autologous platelet lysate in female breast augmentation
    Medical condition: Fat grafting e.g. to the breast to restore small tissue defects is a very common and safe surgical procedure. Its main success among other is depended on the survival rate of the transferred fat ti...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10018065 - General disorders and administration site conditions 10016251 Fat tissue increased PT
    Population Age: Adults Gender: Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-005619-16 Sponsor Protocol Number: Start Date*: 2009-10-07
    Sponsor Name:Erasmus Medical Center
    Full Title: Impact of anti-tumor necrosis factors antibodies treatment on fertility of inflammatory bowel diseases male patients
    Medical condition: Fertility influenced by antiTNF treatment
    Disease: Version SOC Term Classification Code Term Level
    9.1 10016469 Fertility investigations LLT
    Population Age: Adults Gender: Male
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-001863-64 Sponsor Protocol Number: AP301-II-001 Start Date*: 2012-07-03
    Sponsor Name:Apeptico Forschung und Entwicklung GmbH
    Full Title: Proof of concept study in male and female intensive care patients to investigate the clinical effect of repetitive orally inhaled doses of AP301 on alveolar liquid clearance in acute lung injury
    Medical condition: Acute Pulmonary oedema
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 2  3  4  5  6  7  8  9  10  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Jun 01 05:23:51 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA